Synthesis and structure-activity relationships of dimeric peptide antagonists of the human immunoglobulin G-human neonatal Fc receptor (IgG-FcRn) interaction

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1587-1596

  McDonnell, Kevin A ^b   Low, Susan C ^b   Hoehn, Todd ^a   Donnelly, Ryan ^a   Palmieri, Holly ^a   Fraley, Cara ^a   Sakorafas, Paul ^a   Mezo, Adam R ^a  

^a BIOGEN   (United States)

^b BIND Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL GROUP; AMIDE; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOLOGIC AGENT; PEPTIDE; RESIN; SYN 1327; SYN 1436; THIOL; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ARTICLE; CATABOLISM; CONTROLLED STUDY; CYCLIZATION; DIMERIZATION; DISULFIDE BOND; DRUG ACTIVITY; DRUG SYNTHESIS; MOUSE; NONHUMAN; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIMERIZATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, TRANSGENIC; OLIGOPEPTIDES; PEPTIDES, CYCLIC; RECEPTORS, FC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77649196896     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901128z     Document Type: Article

References (23)

1. Roopenian, D. C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7, 715-725.
2. Ober, R. J.; Martinez, C.; Vaccaro, C.; Zhou, J.; Ward, E. S. Visualizing the site and dynamics of IgG salvage by theMHCclass I-related receptor, FcRn. J. Immunol. 2004, 172, 2021-2029.
3. Ober, R. J.; Martinez, C.; Lai, X.; Zhou, J.; Ward, E. S. Exocytosis of IgG as mediated by the receptor, FcRn, an analysis at the singlemolecule level. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11076-11081.
4. Yu, Z.; Lennon, V. A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N. Engl. J. Med. 1999, 340, 227-228.
5. Low, S. C.; Mezo, A. R. Inhibitors of the FcRn:IgG protein: protein interaction. AAPS J. 2009, 11, 432-434.
6. Akilesh, S.; Petkova, S.; Sproule, T. J.; Shaffer, D. J.; Christianson, G. J.; Roopinean, D. C. The MHC class I-like Fc receptor promotes humorally mediated autoimmune diseases. J. Clin. Invest. 2004, 113, 1328-1333.
7. Li, N.; Zhao, M.; Hilario-Vargas, J.; Prisayanh, P.; Warren, S.; Diaz, L. A; Roopenian, D. C.; Liu, Z. Complete FcRn-dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J. Clin. Invest. 2005, 115, 3440-3450.
8. Sesarman, A.; Sitaru, A. G.; Olaru, F.; Zilliken, D.; Sitaru, C. Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita. J. Mol. Med. 2008, 86, 951-959.
9. Lui, L.; Garcia, A. M.; Santoro, H.; Zhang, Y.; McDonnell, K.; Dumont, J.; Bitonti, A. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J. Immunol. 2007, 178, 5390-5398. (Pubitemid 46595326)
10. Petkova, S. B.; Akilesh, S.; Sproule, T. J.; Christianson, G. J.; Khabbaz, H. A.; Brown, A. C.; Presta, L. G.; Meng, Y. G.; Roopenian, D. C. Enhanced hal-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol. 2006, 18, 1759-1769.
11. Mezo, A. R.; McDonnell, K. A.; Tan Hehir, C. A.; Low, S. C.; Palombella, V. J.; Stattel, J. M.; Kamphaus, G. D.; Fraley, C.; Zhang, Y.; Dumont, J. A.; Bitonti, A. J. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2337-2342.
12. Mezo, A. R.; McDonnell, K. A.; Castro, A.; Fraley, C. Structureactivity relationships of a peptide inhibitor of the human FcRn: human IgG interaction. Bioorg. Med. Chem. 2008, 16, 6394-6405.
13. Biernat, M.; Stefanowicz, P.; Zimecki, M.; Szewczuk, Z. Aminoterminal dimerization of peptides on the solid support. Synthesis and biological activity of the immunosuppressive HLA-DR fragments linked by poly(ethylene glycol)s. Bioconjugate Chem. 2006, 17, 1116.
14. Mammen, M.; Choi, S.-K.; Whitesides, G. M. Polyvalent interactions of biological systems: implication for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. 1998, 37, 2754-2794.
15. Li, L.; Xu, B. Multivalent vancomycin and related antibiotics against infectios diseases. Curr. Pharm. Des. 2005, 11, 3111-3124.
16. Griffin, J. H.; Linsell, M. S.; Nodwell, M. B.; Chen, Q.; Pace, J. L.; Quast, K. L.; Krause, K. M.; Farrington, L.; Wu, T. X.; Higgins, D. L.; Jenkins, T. E.; Christensen, B. G.; Judice, J. K. Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. J. Am. Chem. Soc. 2003, 125, 6517-6531.
17. Sanchez, L. M.; Penny, D. M.; Bjorkman, P. J. Stoichiometry of the interaction between the major histocompatibility complex-rated Fc receptor and its Fc ligand. Biochemistry 1999, 38, 9471-9476. (Pubitemid 29347273)
18. Tesar, D. B.; Tiangco, N. E.; Bjorkman, P. J. Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic 2006, 7, 1127-1142.
19. Wrighton, N. C.; Balasubramanian, P.; Barbone, F. P.; Kashyap, A. K.; Farrell, F. X.; Joliffe, L. K.; Barrett, R. W.; Dower, W. J. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat. Biotechnol. 1997, 15, 1261-1265.
20. Shrivastava, A.; von Wronski, M. A.; Sato, A. K.; Dransfield, D. T.; Sexton, D.; Bogdan, N.; Pillai, R.; Nanjappan, P.; Song, B.; Marinelli, E.; DeOliveira, D.; Luneau, C.; Devlin, M.; Muruganandam, A.; Abujoub, A.; Connelly, G.; Wu, Q. L.; Conley, G.; Chang, Q.; Tweedle, M. F.; Ladner, R. C.; Swenson, R. E.; Nunn, A. D. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng., Des. Sel. 2005, 18, 417-424.
21. Vadas, O.; Rose, K. Multivalency - a way to enhance binding avidities and bioactivity - preliminary applications to EPO. J. Pept. Sci. 2007, 13, 581-587.
22. Vadas, O.; Hartley, O.; Rose, K. Characterization of new multimeric erythropoietin receptor agonists. Biopolymers 2008, 90, 496-502.
23. Johnson, D.; Farrell, F. X.; Barbone, F. P.; McMahon, F. J.; Tullai, J.; Kroon, D.; Zivin, R. A.; Mulcahy, L. S.; Jolliffe, L. K. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem. Biol. 1997, 4, 939-950.